Aardvark Therapeutics, Inc. Common Stock
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AARD research report →
Range $1.5 – $4
Price Chart
About the company
Aardvark Therapeutics, Inc. is a biopharmaceutical firm in its clinical development phase, concentrating on developing small-molecule treatments. These therapies are designed to stimulate the body's natural regulatory systems (innate homeostatic pathways) to combat metabolic disorders.
- CEO
- Tien-Li Lee
- IPO
- 2025
- Employees
- 28
- HQ
- San Diego, CA, US
Get TickerSpark's AI analysis on AARD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $20.20M
- P/E
- -0.34
- Fwd P/E
- 6.36
- PEG
- 0.01
- P/S
- 0.00
- P/B
- 0.44
- EV/EBITDA
- 0.47
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -89.27%
- ROIC
- -130.58%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-62,725,000
- Net Income
- $-57,591,000-179.7%
- EPS
- $-2.64-177.9%
- OCF Growth
- -199.5%
- FCF Growth
- -198.2%
- 52W High
- $16.60
- 52W Low
- $0.90
- 50D MA
- $3.43
- 200D MA
- $5.41
- Beta
- 3.81
- RSI (14)
- 29
- Avg Volume
- 642.48K
No earnings-call transcripts are available for AARD yet.
- Free Float
- 50.3%
- Shares Outstanding
- 21.88M
- Float Shares
- 11.01M
of shares held by institutions
75 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Decheng Capital LLC | 3.92M | 0 |
| Citadel Advisors LLC | 1.28M | ▲ 40.39K |
| Laurion Capital Management LP | 1.03M | 0 |
| Vanguard Group Inc | 717.43K | ▲ 161.71K |
| Vanguard Capital Management LLC | 557.93K | ▼ 4.95K |
| Aqr Capital Management LLC | 480.25K | ▲ 345.75K |
| Ecor1 Capital, LLC | 396.19K | ▲ 396.19K |
| Adage Capital Partners Gp, L.L.C. | 300.00K | 0 |
| Blackrock, Inc. | 194.62K | ▲ 7.58K |
| Geode Capital Management, LLC | 139.01K | ▼ 10.84K |
| Marshall Wace, Llp | 132.20K | ▲ 113.13K |
| Cantor Fitzgerald, L. P. | 116.58K | ▲ 49.90K |
Held by 48 ETFs
Biggest fund positions in AARD by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 6, 26 | Lee Tien-Li | other | 549,534 |
| Nov 6, 26 | Lee Tien-Li | other | 203,851 |
| Nov 6, 26 | Lee Tien-Li | other | 40,566 |
| Nov 6, 26 | Lee Tien-Li | sell | 549,534 |
| Nov 6, 26 | Lee Tien-Li | sell | 203,851 |
| Nov 6, 26 | Lee Tien-Li | sell | 40,566 |
| Nov 6, 26 | Sun Nelson | other | 209,826 |
| Nov 6, 26 | Sun Nelson | other | 70,549 |
| Nov 6, 26 | Sun Nelson | other | 23,719 |
| Nov 6, 26 | Sun Nelson | sell | 70,549 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AARD coverage
Recent articles, reports, and earnings notes.
No research on AARD yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AARD report →Aardvark Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Updates
globenewswire.com · Nov 13
Aardvark Therapeutics, Inc. (AARD) Discusses Efficacy and Safety Data From Terminated HERO Phase III and Open-Label Extension Trials Transcript
seekingalpha.com · Oct 23
Aardvark Therapeutics Says Current Prader-Willi Syndrome Drug Data Insufficient
benzinga.com · Oct 23
Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials
globenewswire.com · Oct 23
Aardvark Therapeutics Announces FDA Has Lifted the Clinical Hold on ARD-101 for the Treatment of Prader-Willi Syndrome and Will Host Webcast to Review the Available Exploratory Phase 3 HERO/OLE Data
globenewswire.com · Oct 22
All You Need to Know About Aardvark Therapeutics, Inc. (AARD) Rating Upgrade to Buy
zacks.com · Oct 21
Attention Long-Term Shareholders of Aardvark Therapeutics, Inc. (NASDAQ: AARD); Coastal Financial Corporation (NASDAQ: CCB); Erasca, Inc. (NASDAQ: ERAS); and Power Solutions International, Inc. (NASDAQ: PSIX): Grabar Law Office is Investigating Claims on Your Behalf
globenewswire.com · Oct 15
Pomerantz Law Firm Announces the Filing of a Class Action Against Aardvark Therapeutics, Inc. and Certain Officers and Directors – AARD
globenewswire.com · Oct 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.